Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05371340 · ClinicalTrials.gov registry record · NA
Quercetin's Effect on Bone Health and Inflammatory Markers
A NA study, sponsored by Kennesaw State University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT05371340: Completed NA study, sponsored by Kennesaw State University.
NCT05371340 is a NA study that has completed, run by Kennesaw State University. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05371340, a NA study, has completed, sponsored by Kennesaw State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables, and is considered to be a potent antioxidant with several expected health benefits such as anti-inflammatory effects and bone-conserving properties. Participants will supplement with either Quercetin, or placebo, for 90-days with pre- and post-testing visits.
Primary Outcome
Bone formation marker
Interventions
- DIETARY_SUPPLEMENT Quercetin (500 mg)
- OTHER Placebo (500 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-08-27 |
| Est. Completion | 2020-04-27 |
| Phase | NA |
What the finished NCT05371340 record still lists
NCT05371340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Quercetin (500 mg) is the first listed.
NCT05371340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05371340 about?
NCT05371340 is a clinical study titled "Quercetin's Effect on Bone Health and Inflammatory Markers". Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables, and is considered to be a potent antioxidant with several expected health benefits such as anti-inflammatory effects and bone-conserving properties. Participants will supplement with either Quercetin, or plac...
What is the current status of trial NCT05371340?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2019-08-27. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT05371340?
The interventions under investigation include: Quercetin (500 mg) (DIETARY_SUPPLEMENT), Placebo (500 mg) (OTHER).
Who is sponsoring clinical trial NCT05371340?
This trial is sponsored by Kennesaw State University, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05371340's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI